
Upgrades
Guggenheim upgraded the previous rating for Novo Nordisk A/S (NYSE:NVO) from Neutral to Buy. Novo Nordisk earned $0.94 in the first quarter, compared to $0.88 in the year-ago quarter. The stock has a 52-week-high of $122.16 and a 52-week-low of $78.71. At the end of the last trading period, Novo Nordisk closed at $107.74.